Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Hepatology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Targeted Treatment Improved Survival in Cholangiocarcinoma
February 2026
Matched targeted treatment significantly improved overall survival in advanced cholangiocarcinoma in the Italian ANITA real-world dataset.
Read more
30 Mar 2015
Endosialin an Integral Cog in the Liver Fibrosis Machine
DISCOVERY of a new molecule on the surface of hepatic stellate cells has broadened knowledge of the underlying mechanisms that cause liver fibrosis…
30 Mar 2015
Plant Compounds Represent a Budding Option for Non-Alcoholic Fatty Liver Disease (NAFLD) Treatment
Plant compounds represent a budding option for Non-Alcoholic Fatty Liver Disease (NAFLD) treatment. Read the article and find out more
4 Feb 2015
AbbVie’s VIEKIRAX® (Ombitasvir/Paritaprevir/Ritonavir) and EXVIERA ® (Dasabuvir) Licensed for Use in the UK for the Treatment of Chronic Hepatitis C
MAIDENHEAD, UK, Jan. 19, 2015 – AbbVie’s all-oral, short course (12 weeks for the majority of patients), interferon-free treatments VIEKIRAX®…
27 Jan 2015
Editor’s Pick: Non-Alcoholic Fatty Liver Disease – Changing the Prevalence of Liver Cancer?
Due to its increasing prevalence, exceeding 25% of the Western population, non-alcoholic fatty liver disease (NAFLD) merits recognition as one of the…
27 Jan 2015
Alcohol Dependence and Alcoholic Liver Disease
Summary of Presentations from the H. Lundbeck A/S-Supported Symposium, held at the 49th Annual International Liver Congress, London, United Kingdom…
27 Jan 2015
The Liver Meeting 2014: Summary of Presentations on Genotype 3 HCV Infection from the 65th Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), Held in Boston, MA, USA, on 7th-11th November, 2014
After genotype 1 (GT1), genotype 3 (GT3) is the second most common hepatitis C virus (HCV) genotype worldwide, with an estimated worldwide prevalence of…
27 Jan 2015
Definitions of Acute-On-Chronic Liver Failure: The Past, the Present, and the Future
Acute-on-chronic liver failure (ACLF) is an entity used to define patients with liver cirrhosis presenting with acute decompensation.
27 Jan 2015
Hepatic-Based Inborn Errors of Metabolism
Inborn errors of metabolism (IEMs) are a vast, diverse, and heterogeneous set of genetic disorders. Hepatic-based IEMs are a significant cause of…
Loading posts...
« Previous
1
…
70
71
72
73
74
…
76
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View